14 Nov, EOD - Indian

SENSEX 77580.31 (-0.14)

Nifty 50 23532.7 (-0.11)

Nifty Bank 50179.55 (0.18)

Nifty IT 42390.85 (0.05)

Nifty Midcap 100 54043.1 (0.45)

Nifty Next 50 67408.65 (0.46)

Nifty Pharma 21752 (-0.26)

Nifty Smallcap 100 17601.05 (0.81)

14 Nov, EOD - Global

NIKKEI 225 38642.91 (0.28)

HANG SENG 19426.34 (-0.05)

S&P 5912 (-1.31)

Login/Signup
LOGIN HERE
Cancel

Themis Medicare Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 530199 | NSE Symbol : THEMISMED | ISIN : INE083B01024 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
18-Oct-2024 25-Oct-2024 Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve un-audited standalone and consolidated financial results for the quarter and half year ended 30th September 2024 Please refer to the attachment. (As per BSE Announcement Dated on 25/10/2024)
16-Jul-2024 26-Jul-2024 Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve the unaudited financial results for the quarter ended 30th June 2024. As per the attachment (As Per BSE Announcement Dated on: 26/07/2024)
06-Jun-2024 06-Jun-2024 Change in Directors Please find our intimation on the captioned subject.
03-May-2024 14-May-2024 Final Dividend THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve Please refer our intimation on the captioned subject. 1) Approval of the Financial Results for the FY 2023-24 2) Final Dividend for the FY 2023-24 (As Per BSE Announcement Dated on: 14/05/2024)
29-Jan-2024 10-Feb-2024 Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Un-audited Standalone and Consolidated Financial Results for the quarter ended 31st December 2023. Please refer our attached intimation (As per BSE Announcement Dated on 10/02/2024)
25-Oct-2023 04-Nov-2023 Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results for the quarter and half year ended on 30th September 2023. Further in continuation of our Letter dated 28th September 2023 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors / Designated Employees from the opening of the trading hours on Sunday 1st October 2023 which shall remain closed till the closure of trading hours on 6th November 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Saturday, 4th November, 2023, has inter-alia approved the following: a) The Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30th September, 2023. A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30th September, 2023 together with Limited Review Report issued by M/s. Krishaan & Co., Chartered Accountants is enclosed herewith. b) The proposal to enter into Master Service Agreement with its Related Party and Associate Company, viz. Gujarat Themis Biosyn Limited. The details required as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 read with Regulation 30A of the Listing Regulations are enclosed as Annexure - I. This may be taken as compliance under the Listing Regulations. Please find enclosed financial results for the quarter and half-year ended 30th September 2023 (As Per BSE Announcement Dated on 04.11.2023)
07-Sep-2023 07-Sep-2023 Change in Directors We would like to inform that Board of Directors of the Company has approved and passed resolutions (as mentioned in the attached intimation) by circulation on September 7, 2023. Kindly take the above intimation on record.
02-Aug-2023 10-Aug-2023 Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Saturday 12th August 2023 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results for the Quarter ended on 30th June 2023. Further in continuation of our Letter dated 27th June 2023 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Saturday 1st July 2023 which shall remain closed till the closure of trading hours on Monday 14th August 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. This is for your information and record. THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve This has reference to our letter dated 02nd August, 2023 informing that a meeting of the Board of Directors of Themis Medicare Limited (''the Company'') to be held on Saturday, 12th August, 2023 inter alia, to consider and approve the Un-audited Standalone Financial Results for the Quarter ended on 30th June, 2023. The said meeting is now preponed and rescheduled and will now be held on Thursday, 10th August,2023. (As per BSE Announcement Dated on 03/08/2023) Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Thursday, August 10, 2023, has inter-alia approved the following: a) The Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June, 2023. A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June, 2023 together with Limited Review Report issued by M/s. Krishaan & Co., Chartered Accountants is enclosed herewith. b) Incorporation of a subsidiary company in India as private limited company. This may be taken as compliance under the Listing Regulations. Please find attached unaudited results for the quarter ended June 30, 2023 (Standalone and Consolidated) (As Per BSE Announcement dated on 10.08.2023)
04-May-2023 13-May-2023 Accounts THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2023 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Saturday 13.05.2023 inter alia to transact the following business: 1.To consider the Audited Financial Results for the Quarter/Year ended on 31.03.2023 2.To consider recommending Dividend if any on the equity shares of the Company for the financial year 2022-23. 3.To consider and approve the proposal to sub-divide/split the Equity Shares of the Company in such manner as may be determined by the Board of Directors and subject to approval of the Shareholders and such authorities as may be required. The Board of Directors at its meeting held today, considered and approved the following matters: 1. Approved the Audited Standalone and Consolidated financial results for the Quarter and Year ended 31st March, 2023. A copy of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 2023 is enclosed herewith. (Annexure I) 2. Recommended dividend for Financial Year ended 31.03.2023 of Rs. 5/- i.e. @ 50% per equity share having face value of Rs.10/- aggregating to Rs. 4,60,13,850/-. The payment is subject to the approval of shareholders at the ensuing AGM. 3. Appointment of M/s. B.J. D. Nanabhoy & Co., as the Cost Auditors of the Company for the FY 2023-24. 2. Recommended dividend for Financial Year ended 31.03.2023 of Rs. 5/- i.e. @ 50% per equity share having face value of Rs.10/- aggregating to Rs. 4,60,13,850/-. The payment is subject to the approval of shareholders at the ensuing AGM. (As per BSE Announcement Dated on 13/05/2023)
27-Jan-2023 03-Feb-2023 Quarterly Results Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 ,inter alia, to consider and approve With respect to the captioned subject, please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Friday 03rd February, 2023 inter alia, to consider, the Un-audited Standalone and Consolidated Financial Results for the Quarter and nine months ended on 31st December, 2022. Further, in continuation of our Letter dated 26th December 2022, the Trading Window in respect of dealing in the Company's Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Sunday, 1st January, 2023, which shall remain closed till the closure of trading hours on 05th February, 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time. (As Per BSE Announcement dated on 27.01.2023) The Board of Directors at its meeting held today, considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended 31st December 2022. A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended 31st December, 2022 together with Limited Review Report issued by Krishaan & Co., Chartered Accountants is enclosed herewith. This may be taken as compliance under the Listing Regulations. (As per BSE Announcement Dated on 03/02/2023)
28-Oct-2022 07-Nov-2022 Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Wednesday 7th November 2022 inter alia to consider the Un-audited Standalone and Consolidated Financial Results for the quarter and half year ended on 30thSeptember 2022. Further in continuation of our Letter dated 27th September 2022 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Saturday 1stOctober 2022 which shall remain closed till the closure of trading hours on 9th November 2022 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. In continuation to our letter dated 28th October, 2022, about the intimation of Board Meeting to be held on, 7th November, 2022. There was a typographical error where by Monday was inadvertently typed as Wednesday. This has to be read as Monday, 7th November, 2022 instead of Wednesday. (As Per BSE Announcement Dated on 31.10.2022) Further to our intimation about the outcome of the Board Meeting held on 7th November, 2022, we have to intimate that the Board of Directors (the Board) vide a resolution passed by circulation on 9th November, 2022 has rescinded the following resolution passed by the Board at its meeting held on 7th November, 2022 due to sudden unforeseen circumstances: Resolution authorising the Company for Purchase of 9,39,597 equity shares (representing 6.47%) of Gujarat Themis Biosyn Limited, a company listed on the BSE Limited, from Pharmaceutical Business Group [India] Limited (PBG India) at Rupees 745 per share aggregating to Rupees Seventy crores. This intimation is also being uploaded on Company's website https://www.themismedicare.com/ (As Per BSE Announcement Dated on 09/11/2022)
19-Jul-2022 28-Jul-2022 Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2022 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Thursday28th July 2022 inter alia to consider the Un-audited Standalone and Consolidated Financial Results for the quarter ended on 30th June 2022. We request you to take the same on record.
12-May-2022 21-May-2022 Final Dividend THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2022 inter alia to consider and approve Please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Saturday 21.05.2022 inter alia to transact the following business: 1. To consider the Audited Financial Results for the Quarter/Year ended on 31.03.2022 2. To consider recommending Dividend if any on the equity shares of the Company for the financial year 2021-22. Further in continuation of our Letter dated 29.03.2022 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Friday 01.04.2022 which shall remain closed till the closure of trading hours on 23.05.2022 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. Themis Medicare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 21, 2022, inter alia, has recommended dividend for Financial Year ended March 31, 2022 of Rs. 5.00/- (Rupees Five only) i.e. @ 50% per equity share having face value of Rs. 10/-, aggregating to Rs. 460.02 lacs. The payment is subject to the approval of shareholders at the ensuing AGM. (As Per BSE Announcement Dated on 23/05/2022) 1. Approved the Audited Standalone and Consolidated financial results for the Quarter and Year ended 31st March, 2022. A copy of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 2022 is enclosed herewith. (Annexure I) 2. Recommended dividend for Financial Year ended 31.03.2022 of Rs.5.00/- (Rupees Five only) i.e. @ 50% per equity share having face value of Rs.10/-, aggregating to Rs.460.02 lacs. The payment is subject to the approval of shareholders at the ensuing AGM. 3. Considered the appointment of M/s. B.J. D. Nanabhoy & Co., Cost Accountant as the Cost Auditors of the Company for the FY 2022-23. 4. Appointed CS Shirish Shetye (FCS 1926), or failing him, CS Aparna P. Joshi (FCS 7172) or failing her, CS Vaibhav S. Velankar (FCS 11448), designated partners of SAV & Associates LLP, Practicing Company Secretaries, as the Scrutinizer for conducting E-Voting and Poll at the 52nd Annual General Meeting. (As Per BSE Announcement Dated on 21.05.2022)
31-Jan-2022 11-Feb-2022 Quarterly Results THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Friday 11th February 2022 inter alia to consider the Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December 2021. Further in continuation of our Letter dated 29th December 2021 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Saturday 01st January 2022 which shall remain closed till the closure of trading hours on 13th February 2022 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. This is for your information and record. The Board of Directors at its meeting held today, considered and approved the following matters: 1. Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended 31.12.2021. A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended 31.12.2021 is enclosed herewith. 2. Appointed M/s. SAV & Associates LLP as Secretarial Auditor for the financial year 2021-22 for the purpose of conducting Secretarial Audit. 3. A Risk Management Committee of the Company has been constituted. 4. The Board has formulated a Dividend Distribution Policy. 5. The Board of Directors took note of the following: a) The tenure of appointment of Mrs. Jayshree D Patel, Whole Time Director ends on 27.03.2022 b) Mrs. Jayshre D. Patel will not be seeking reappointment. c) Mrs. Jayshree D. Patel will be stepping down as Director w.e.f. closure of business hours on 27.03.2022 This may be taken as compliance under the Listing Regulations. (As Per BSE Announcement dated on 11.02.2022)
02-Nov-2021 12-Nov-2021 Quarterly Results Quarterly Results 1. Approved the Unaudited Standalone and Consolidated financial results for the Quarter and HalfYear ended 30th September, 2021.A copy of Financial Results for the Quarter and Half Year ended 30th September, 2021 is enclosed herewith. Also attached financial result highlight 2. Appointment of Mr. BhaskerVembanIyer(DIN : 00480341) as an Additional Independent Director . 3. Re-appointment of Dr. Dinesh S. Patel (DIN : 00033273)Executive Vice Chairman of the Company,whose current term will be ending on 13th February, 2022,, whose current term will be ending on 13th February, 2022. During the tenure of his reappointment he will be completing 75 years of age. The Board also approved his continuation as Director and Executive Vice Chairman beyond the age of 75 years subject to the approval of the Shareholders. 4. Re-appointment of Dr.Sachin D. Patel(DIN : 00033353)as Managing Director & CEO of the Company,whose current term will be ending on 13th February, 2022. 1. Approved the Unaudited Standalone and Consolidated financial results for the Quarter and HalfYear ended 30th September, 2021.A copy of theUnaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2021 2. Appointment of Mr. BhaskerVembanIyer(DIN : 00480341) as an Additional Independent Director 3. Re-appointment of Dr. Dinesh S. Patel (DIN : 00033273)Executive Vice Chairman of the Company,whose current term will be ending on 13th February, 2022,, whose current term will be ending on 13th February, 2022. 4. Re-appointment of Dr.Sachin D. Patel(DIN : 00033353)as Managing Director & CEO of the Company,whose current term will be ending on 13th February, 2022. The Board has re-appointed him as Managing Director & CEO for further period of 5 years with effect from 14th February,2022subject to approval by the shareholders.( Annexure IV) 2. Appointment of Mr. BhaskerVembanIyer(DIN : 00480341) as an Additional Independent Director with effect from 12th November,2021. 3. Re-appointment of Dr. Dinesh S. Patel (DIN : 00033273)Executive Vice Chairman of the Company,whose current term will be ending on 13th February, 2022,, whose current term will be ending on 13th February, 2022. 4. Re-appointment of Dr.Sachin D. Patel(DIN : 00033353)as Managing Director & CEO of the Company,whose current term will be ending on 13th February, 2022. (As per BSE Announcement Dated on 12/11/2021)
1 2